Literature DB >> 10219602

[Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire].

J M Raymond1, P Marquis, D Bechade, D Smith, H Mathiex Fortunet, T Poynard, J P Galmiche, M Amouretti.   

Abstract

UNLABELLED: Quality of life is frequently impaired in patients with gastro-esophageal reflux. The aim of this study was the validation of a new specific quality of life questionnaire in patients with gastro-esophageal reflux.
METHODS: A questionnaire was generated as follows: a) item generation with patients, b) item reduction, c) psychometric validation and comparison to a reference questionnaire (SF36) in patients with symptomatic gastro-esophageal reflux, d) assessment of reproducibility, and e) responsiveness over time.
RESULTS: The primary questionnaire was made of 104 items. Two hundred twenty three patients were enrolled, 38 items were selected in 7 dimensions. One item was deleted following a new analysis conducted in 349 patients. Cronbach coefficient ranged from 0.84 to 0.91 for the specific questionnaire and from 0.78 to 0.90 for the SF36 questionnaire. Dimensions of specific questionnaire and SF36 were correlated. Quality of life was more impaired in patients with more frequent symptoms. Severity of endoscopic lesions was partly correlated with impaired quality-of-life. Reproducibility and responsiveness over time were correct. The final valid questionnaire was made of 37 items in 7 dimensions.
CONCLUSION: This work is the first validation of a specific questionnaire in French which has the ability to measure quality of life in patients with gastro-esophageal reflux. The use of this questionnaire during therapeutic trials might allow to be more accurate in assessment of treatment efficacy.

Entities:  

Mesh:

Year:  1999        PMID: 10219602

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  8 in total

Review 1.  Questionnaire based gastroesophageal reflux disease (GERD) assessment scales.

Authors:  V Pratap Mouli; Vineet Ahuja
Journal:  Indian J Gastroenterol       Date:  2011-07-23

Review 2.  Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature.

Authors:  A M Rentz; C Battista; E Trudeau; R Jones; P Robinson; S Sloan; S Mathur; L Frank; D A Revicki
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome.

Authors:  Pier Alberto Testoni; Cristian Vailati; Sabrina Testoni; Maura Corsetti
Journal:  Surg Endosc       Date:  2011-12-15       Impact factor: 4.584

4.  Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study.

Authors:  Pier Alberto Testoni; Sabrina Testoni; Giorgia Mazzoleni; Cristian Vailati; Sandro Passaretti
Journal:  Surg Endosc       Date:  2014-12-06       Impact factor: 4.584

Review 5.  The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.

Authors:  Manishi Prasad; Anne M Rentz; Dennis A Revicki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients.

Authors:  Pier Alberto Testoni; Maura Corsetti; Salvatore Di Pietro; Antonio Gianluca Castellaneta; Cristian Vailati; Enzo Masci; Sandro Passaretti
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 7.  Choosing the right survey-patient reported outcomes in esophageal surgery.

Authors:  Maira Ahmed; Angus Lau; Dhruvin H Hirpara; Biniam Kidane
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

8.  Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years.

Authors:  Pier Alberto Testoni; Sabrina Testoni; Giovanni Distefano; Giorgia Mazzoleni; Lorella Fanti; Sandro Passaretti
Journal:  Endosc Int Open       Date:  2019-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.